Ignite Creation Date:
2025-12-25 @ 4:50 AM
Ignite Modification Date:
2026-02-26 @ 12:03 PM
Study NCT ID:
NCT01847118
Status:
UNKNOWN
Last Update Posted:
2015-03-24
First Post:
2013-04-26
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Phase Ia, Dose Escalation Study of Humanized Anti-VEGF Monoclonal Antibody (Sevacizumab) Injection in Patients With Advanced or Metastatic Solid Tumors
Sponsor:
Jiangsu Simcere Pharmaceutical Co., Ltd.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2013-04
Start Date Type:
None
Primary Completion Date:
2015-11
Primary Completion Date Type:
ESTIMATED
Completion Date:
2015-11
Completion Date Type:
ESTIMATED
First Submit Date:
2013-04-26
First Submit QC Date:
None
Study First Post Date:
2013-05-06
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2015-03-22
Last Update Post Date:
2015-03-24
Last Update Post Date Type:
ESTIMATED